Skip to main content

Table 1 Patients’ characteristics at baseline

From: Anti-inflammatory and morphologic effects of pitavastatin on carotid arteries and thoracic aorta evaluated by integrated backscatter trans-esophageal ultrasound and PET/CT: a prospective randomized comparative study with pravastatin (EPICENTRE study)

  Pitavastatin (n = 10) Pravastatin (n = 10) p value
Age, year 68 ± 5 64 ± 11 0.26
Man, n (%) 7 (70) 8 (80) >0.99
Height, cm 161.3 ± 6.1 162.5 ± 11.3 0.78
Body weight, kg 65.0 ± 9.1 63.5 ± 10.6 0.73
Main history, n (%)    
Hypertension 5 (50) 5 (50) >0.99
Diabetes mellitus 4 (40) 2 (20) 0.36
Smoking, n (%) 6 (60) 5 (50) 0.67
Valvular heart disease 3 (30) 2 (20) 0.63
Medications, n (%)    
ARBs or ACEIs 2 (20) 5 (50) 0.18
Beta-blockers 3 (30) 3 (30) >0.99
Ca channel blockers 4 (40) 3 (30) 0.67
  1. ARBs: angiotensin II receptor blockers, ACEIs: angiotensin-converting enzyme inhibitors, Ca: calcium.